Iovance Biotherapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Iovance Biotherapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 8 currently recruiting 3 completed early-phase tilt top decile by trial count

Iovance Biotherapeutics: 12 sponsored US clinical trials, 8 recruiting.

Iovance Biotherapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Melanoma, with 5 trials.

Top-decile sponsor footprint

Iovance Biotherapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 2

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

NCT07288203
RECRUITING Phase 1

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

NCT06940739
RECRUITING Phase 2

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

NCT06481592
RECRUITING Phase 1

Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

NCT06566092
RECRUITING Phase 3

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904
RECRUITING Phase 1

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

NCT05361174
RECRUITING Phase 2

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103
RECRUITING Phase 2

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

NCT03645928
COMPLETED Phase 1

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

NCT04155710
TERMINATED Phase 2

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

NCT03108495
COMPLETED Phase 2

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

NCT03083873
COMPLETED Phase 2

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

NCT02360579

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 7
Phase 3 1

Therapeutic Areas

Metastatic Melanoma 5
Unresectable Melanoma 4
Melanoma 2
Stage IV Non-small Cell Lung Cancer 1
Stage III Non-small Cell Lung Cancer 1
Melanoma (Skin Cancer) 1
Primary Central Nervous System Carcinoma 1
Soft Tissue Sarcoma 1
Ocular Melanoma 1
Squamous Cell Carcinoma of the Head and Neck 1

What is open in the Iovance Biotherapeutics pipeline

8 recruiting of 12 indexed (67% open); 3 completed (25%).

Phase mix: 1 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Metastatic Melanoma (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Iovance Biotherapeutics: open-pipeline peers nationwide

Peers matched on 12 registered trials and 67% open enrollment, not the therapeutic-area sidebar.

Iovance Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 2468101214 0%20%40%60%80% Total trials Recruiting share Iovance BiotherapeuticsAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsAbbisko Therapeutics CoABL BioAccelerated Cure Project for Multiple SclerosisAdvanced Reconstructive Surgery Alliance
Iovance Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Iovance Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 67% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Iovance Biotherapeutics page

12 registered trials is a research-attention snapshot, not an endorsement of Iovance Biotherapeutics or any single study.

  • 8 of Iovance Biotherapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Metastatic Melanoma is the condition Iovance Biotherapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Melanoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Iovance Biotherapeutics pipeline card: 12 registered trials from official public datasets.Report a data error.